Mechanisms And Prognosis of Stroke-Heart Syndrome

Last updated: April 23, 2025
Sponsor: Chensheng Pan
Overall Status: Active - Recruiting

Phase

N/A

Condition

Arrhythmia

Heart Defect

Stroke

Treatment

N/A

Clinical Study ID

NCT06954103
TJ-IRB202502010
  • Ages > 18
  • All Genders

Study Summary

The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients admitted within 48 hours of onset, confirmed by CT/MRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke).

  2. Moderate-to-severe stroke with NIHSS ≥ 5.

Exclusion

Exclusion Criteria:

  1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury,etc.).

  2. Brain dysfunction caused by other major neurological disorders than stroke (such asbrain tumors, epilepsy, Parkinson's disease, etc.).

  3. Transient ischemic attack (TIA) and subarachnoid hemorrhage (SAH).

  4. History of cardiac diseases (such as coronary heart disease, heart failure, severearrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, orundiagnosed significant cardiac symptoms).

  5. Concomitant systemic diseases such as renal failure (eGFR < 30), autoimmunedisorders, severe infections, etc.

  6. History of dementia, depression, or other psychiatric disorders.

  7. Poor compliance and inability to cooperate with follow-up.

Study Design

Total Participants: 658
Study Start date:
March 01, 2025
Estimated Completion Date:
April 01, 2028

Connect with a study center

  • Department of Neurology, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology

    Wuhan, Hubei 430030
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.